INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,678,643 | +93.9% | 252,354 | +15.7% | 0.00% | 0.0% |
| Q2 2023 | $2,412,904 | +2.2% | 218,165 | +24.1% | 0.00% | 0.0% |
| Q1 2023 | $2,360,738 | -1.8% | 175,781 | -9.5% | 0.00% | 0.0% |
| Q4 2022 | $2,403,281 | +63.8% | 194,283 | +84.7% | 0.00% | – |
| Q3 2022 | $1,467,000 | +8.0% | 105,164 | +7.0% | 0.00% | – |
| Q2 2022 | $1,358,000 | -21.0% | 98,307 | -7.0% | 0.00% | – |
| Q1 2022 | $1,720,000 | +2.4% | 105,729 | +2.6% | 0.00% | – |
| Q4 2021 | $1,679,000 | +21.4% | 103,085 | +10.6% | 0.00% | – |
| Q3 2021 | $1,383,000 | -14.0% | 93,222 | +15.8% | 0.00% | – |
| Q2 2021 | $1,608,000 | -32.2% | 80,499 | -21.6% | 0.00% | – |
| Q1 2021 | $2,371,000 | -8.6% | 102,690 | -2.2% | 0.00% | -100.0% |
| Q4 2020 | $2,594,000 | -40.8% | 105,034 | -0.6% | 0.00% | 0.0% |
| Q3 2020 | $4,379,000 | -17.3% | 105,619 | -4.5% | 0.00% | 0.0% |
| Q2 2020 | $5,296,000 | -21.1% | 110,560 | +3.7% | 0.00% | -50.0% |
| Q1 2020 | $6,715,000 | -52.7% | 106,656 | -6.8% | 0.00% | -50.0% |
| Q4 2019 | $14,188,000 | +115.9% | 114,495 | +15.6% | 0.00% | +100.0% |
| Q3 2019 | $6,573,000 | -17.6% | 99,050 | -1.2% | 0.00% | 0.0% |
| Q2 2019 | $7,978,000 | -25.4% | 100,263 | +4.9% | 0.00% | -33.3% |
| Q1 2019 | $10,689,000 | +12.3% | 95,556 | +1.2% | 0.00% | 0.0% |
| Q4 2018 | $9,517,000 | -19.2% | 94,419 | +1.3% | 0.00% | 0.0% |
| Q3 2018 | $11,780,000 | +56.2% | 93,227 | +3.7% | 0.00% | +50.0% |
| Q2 2018 | $7,542,000 | +71.3% | 89,885 | +25.6% | 0.00% | +100.0% |
| Q1 2018 | $4,402,000 | +0.8% | 71,545 | -4.3% | 0.00% | 0.0% |
| Q4 2017 | $4,368,000 | -2.7% | 74,761 | -3.3% | 0.00% | 0.0% |
| Q3 2017 | $4,487,000 | -48.2% | 77,310 | +8.1% | 0.00% | -50.0% |
| Q2 2017 | $8,662,000 | +12.1% | 71,549 | +4.8% | 0.00% | 0.0% |
| Q1 2017 | $7,725,000 | +14.7% | 68,302 | +10.2% | 0.00% | 0.0% |
| Q4 2016 | $6,735,000 | -34.4% | 61,990 | -0.7% | 0.00% | -33.3% |
| Q3 2016 | $10,274,000 | +8.4% | 62,422 | -6.0% | 0.00% | 0.0% |
| Q2 2016 | $9,476,000 | +6.3% | 66,416 | -4.3% | 0.00% | 0.0% |
| Q1 2016 | $8,916,000 | -11.6% | 69,406 | +2.8% | 0.00% | 0.0% |
| Q4 2015 | $10,081,000 | -14.5% | 67,500 | -5.1% | 0.00% | -25.0% |
| Q3 2015 | $11,795,000 | -25.7% | 71,109 | +8.2% | 0.00% | 0.0% |
| Q2 2015 | $15,865,000 | -3.7% | 65,727 | +12.5% | 0.00% | 0.0% |
| Q1 2015 | $16,475,000 | +137.5% | 58,420 | +31.4% | 0.00% | +100.0% |
| Q4 2014 | $6,937,000 | -77.2% | 44,462 | -65.4% | 0.00% | -75.0% |
| Q3 2014 | $30,382,000 | +76.7% | 128,368 | +76.7% | 0.01% | +300.0% |
| Q2 2014 | $17,194,000 | +27.2% | 72,660 | +77.3% | 0.00% | -50.0% |
| Q1 2014 | $13,512,000 | +329.6% | 40,971 | -11.0% | 0.00% | +300.0% |
| Q4 2013 | $3,145,000 | -47.9% | 46,052 | -47.3% | 0.00% | 0.0% |
| Q3 2013 | $6,032,000 | +358.4% | 87,360 | +197.6% | 0.00% | – |
| Q2 2013 | $1,316,000 | – | 29,357 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |